Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Kathleen Rodgers, PhD

    TitleAssociate Professor
    SchoolSchool of Pharmacy
    DepartmentClinical Pharmacy and Pharmaceutical Econ. and Policy
    AddressPSC 530
    Health Sciences Campus
    Los Angeles California 90089-9121
    Phone+1 323 442 2574
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Kathleen E. Rodgers, PhD, is an Associate Professor in the Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy in the School of Pharmacy at the University of Southern California. Throughout her career, Dr. Rodgers has conducted research into a broad array of topics including gynecological cancers, medical device safety, drug effectiveness and toxicology.

      Since joining USC in 1986, she has been interested in applied research. Early in her career, she continued her doctoral research in the immunotoxicology of organophosphate pesticides. Her research interests also included the development of an immunoassay for gynecological cancers and an understanding of the process of peritoneal healing and the formation of intraperitoneal adhesions. After identification of key processes in these healing events, one focus became the identification of therapeutic interventions by which adhesions can be prevented. Further, she discovered that molecules generated by the renin angiotensin system have potential therapeutic benefit.

      The current focus of her basic science research is the cellular and molecular mechanisms by which angiotensin peptides accelerated tissue regeneration. Studies have shown that there is a primary effect on adult stem cell proliferation and homing. Further, there is an expertise within her laboratory in development of animal models relevant to surgical injuries and to provide and conduct developmental plans to optimized product delivery and efficacy. As her focus has been to provide translational assistance from the bench to the patient, she has spent time consulting for companies interested in developing products within her areas of expertise. Further, she has developed recommended panels of safety studies to allow conduct of clinical trials under FDA and EU supervision. Most recently, her basic research has developed to the point that three clinical trials involving the molecules developed through her research will soon be initiated.

      She is the holder of 42 US Patents and corresponding international filings that protect the commercial products that might be developed. The University is the holder of these patents and has recently licensed these patents to small biotechnology companies. She provided pre-clinical support, the oversight of the toxicological studies to enable the regulatory filings to allow clinical trials and input on the development of clinical protocols.

      National and international organizations that she has worked with include: (1) World Health Organization on three committees ((a) Immunotoxicology of Pesticides; (b) Women’s Health and Implantable Contraceptive; (c) Autoimmunity and Environmental Influences) ; (2) National Research Council (Commision of Life Sciences, Committee on Toxicology Board on Environmental Studies and Toxicology; Subcommittee on Biological Markers of Immunotoxicology); (3) Institute of Medicine (Committee to Review Health Effects in Vietnam Veterans of Exposure to Herbicides).


      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Rodgers K, Tan A, Kim L, Espinoza T, Meeks C, Johnston W, Maulhardt H, Donald M, Hill C, diZerega GS. Development of a guinea pig cutaneous radiation injury model using low penetrating X-rays. Int J Radiat Biol. 2016 Aug; 92(8):434-43. PMID: 27258737.
        View in: PubMed
      2. Abdallah WF, Louie SG, Zhang Y, Rodgers K, Sivok E, S diZerega G, Humayun MS. NorLeu3A(1-7) Accelerates Clear Corneal Full Thickness Wound Healing. Invest Ophthalmol Vis Sci. 2016 Apr 1; 57(4):2187-94. PMID: 27116546.
        View in: PubMed
      3. Papinska AM, Soto M, Meeks CJ, Rodgers K. Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacol Res. 2016 May; 107:372-80. PMID: 26956523.
        View in: PubMed
      4. Aboye T, Meeks CJ, Majumder S, Shekhtman A, Rodgers K, Camarero JA. Design of a MCoTI-Based Cyclotide with Angiotensin (1-7)-Like Activity. Molecules. 2016; 21(2). PMID: 26821010.
        View in: PubMed
      5. Rodgers K, Papinska A, Mordwinkin N. Regulatory aspects of small molecule drugs for heart regeneration. Adv Drug Deliv Rev. 2016 Jan 15; 96:245-52. PMID: 26150343.
        View in: PubMed
      6. Jadhav SS, Meeks CJ, Mordwinkin NM, Espinoza TB, Louie SG, diZerega GS, Rodgers K. Effect of combined radiation injury on cell death and inflammation in skin. Apoptosis. 2015 Jul; 20(7):892-906. PMID: 25772546.
        View in: PubMed
      7. Asatryan L, Khoja S, Rodgers K, Alkana RL, Tsukamoto H, Davies DL. Chronic ethanol exposure combined with high fat diet up-regulates P2X7 receptors that parallels neuroinflammation and neuronal loss in C57BL/6J mice. J Neuroimmunol. 2015 Aug 15; 285:169-79. PMID: 26198936.
        View in: PubMed
      8. Irwin RW, Solinsky CM, Loya CM, Salituro FG, Rodgers K, Bauer G, Rogawski MA, Brinton RD. Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease. PLoS One. 2015; 10(6):e0128313. PMID: 26039057.
        View in: PubMed
      9. Rodgers K, Bolton LL, Verco S, diZerega GS. NorLeu(3)-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers. Adv Wound Care (New Rochelle). 2015 Jun 01; 4(6):339-345. PMID: 26029484.
        View in: PubMed
      10. Yardley MM, Huynh N, Rodgers K, Alkana RL, Davies DL. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol. 2015 Sep; 49(6):553-9. PMID: 26095588.
        View in: PubMed
      11. Rodgers K, Peterson KJ, Maulhardt HA, Dizerega GS. Angiotensin 1 - 7 stimulation of platelet recovery. Expert Opin Investig Drugs. 2014 Apr; 23(4):551-9. PMID: 24555825.
        View in: PubMed
      12. Rodgers K, Dizerega GS. Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target. Front Endocrinol (Lausanne). 2013; 4:157. PMID: 24167502.
        View in: PubMed
      13. Rodgers K, Espinoza TB, Roda N, Meeks CJ, Dizerega GS. Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1235-45. PMID: 24091850.
        View in: PubMed
      14. Shah M, Edman MC, Janga SR, Shi P, Dhandhukia J, Liu S, Louie SG, Rodgers K, Mackay JA, Hamm-Alvarez SF. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. J Control Release. 2013 Nov 10; 171(3):269-79. PMID: 23892265.
        View in: PubMed
      15. Hajjar I, Rodgers K. Do angiotensin receptor blockers prevent Alzheimer's disease? Curr Opin Cardiol. 2013 Jul; 28(4):417-25. PMID: 23703253.
        View in: PubMed
      16. Pham H, Schwartz BM, Delmore JE, Reed E, Cruickshank S, Drummond L, Rodgers K, Peterson KJ, diZerega GS. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother Pharmacol. 2013 Apr; 71(4):965-72. PMID: 23370663.
        View in: PubMed
      17. Jadhav SS, Sharma N, Meeks CJ, Mordwinkin NM, Espinoza TB, Roda NR, DiZerega GS, Hill CK, Louie SG, Rodgers K. Effects of combined radiation and burn injury on the renin-angiotensin system. Wound Repair Regen. 2013 Jan-Feb; 21(1):131-40. PMID: 23231670.
        View in: PubMed
      18. Mordwinkin NM, Ouzounian JG, Yedigarova L, Montoro MN, Louie SG, Rodgers K. Alteration of endothelial function markers in women with gestational diabetes and their fetuses. J Matern Fetal Neonatal Med. 2013 Mar; 26(5):507-12. PMID: 23046386.
        View in: PubMed
      19. Balingit PP, Armstrong DG, Reyzelman AM, Bolton L, Verco SJ, Rodgers K, Nigh KA, Dizerega GS. NorLeu(3) -A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen. 2012 Jul; 20(4):482-90. PMID: 22672145.
        View in: PubMed
      20. Rodgers K, Espinoza T, Roda N, Meeks CJ, Hill C, Louie SG, Dizerega GS. Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation. Int J Radiat Biol. 2012 Jun; 88(6):466-76. PMID: 22433112.
        View in: PubMed
      21. Mordwinkin NM, Meeks CJ, Jadhav SS, Espinoza T, Roda N, Dizerega GS, Louie SG, Rodgers K. Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow. Endocrinology. 2012 May; 153(5):2189-97. PMID: 22434085.
        View in: PubMed
      22. Rodgers K, Verco S, Bolton L, Dizerega G. Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7). Expert Opin Investig Drugs. 2011 Nov; 20(11):1575-81. PMID: 21973177.
        View in: PubMed
      23. Mordwinkin NM, Russell JR, Burke AS, Dizerega GS, Louie SG, Rodgers K. Toxicological and toxicokinetic analysis of angiotensin (1-7) in two species. J Pharm Sci. 2012 Jan; 101(1):373-80. PMID: 21858825.
        View in: PubMed
      24. Rodgers K, Burleson FG, Burleson GR, Wolfsegger MJ, Lewis KM, Redl H. Two-component polyethylene glycol surgical sealant influence on intraperitoneal infection in a refined rodent model. Am J Obstet Gynecol. 2010 Nov; 203(5):494.e1-6. PMID: 20810099.
        View in: PubMed
      25. Cui H, Gensini M, Kataria R, Twaddle T, Zhang J, Wadsworth S, Petrilli J, Rodgers K, diZerega G, Cooper K. Reducing post-surgical adhesions utilizing a drug-enhanced device: sodium carboxymethylcellulose aqueous gel/poly(p-dioxanone) and Tranilast. Biomed Mater. 2009 Feb; 4(1):015001. PMID: 18981543.
        View in: PubMed
      26. Petrilli J, Wadsworth S, Cooper K, Rodgers K, Siekierka J, diZerega GS. Tranilast: a pharmaceutical candidate for reduction of adhesions using a novel approach. Semin Reprod Med. 2008 Jul; 26(4):341-8. PMID: 18756411.
        View in: PubMed
      27. Hwang J, Rodgers K, Oliver JC, Schluep T. Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int J Nanomedicine. 2008; 3(3):359-71. PMID: 18990945.
        View in: PubMed
      28. Cooper K, Young J, Wadsworth S, Cui H, diZerega GS, Rodgers K. Reduction of post-surgical adhesion formation with tranilast. J Surg Res. 2007 Aug; 141(2):153-61. PMID: 17560610.
        View in: PubMed
      29. diZerega GS, Cortese S, Rodgers K, Block KM, Falcone SJ, Juarez TG, Berg R. A modern biomaterial for adhesion prevention. J Biomed Mater Res B Appl Biomater. 2007 Apr; 81(1):239-50. PMID: 16969823.
        View in: PubMed
      30. Rodgers K, Ellefson DD, Espinoza T, Hsu YH, diZerega GS, Mehrian-Shai R. Expression of intracellular filament, collagen, and collagenase genes in diabetic and normal skin after injury. Wound Repair Regen. 2006 May-Jun; 14(3):298-305. PMID: 16808808.
        View in: PubMed
      31. Rodgers K, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. 2006 May; 57(5):559-68. PMID: 16096787.
        View in: PubMed
      32. Rodgers K. Technology evaluation: Chrysalin (Orthologic). Curr Opin Mol Ther. 2005 Jun; 7(3):264-72. PMID: 15977425.
        View in: PubMed
      33. Rodgers K, Ellefson DD, Espinoza T, Roda N, Maldonado S, Dizerega GS. Effect of NorLeu3-A(1-7) on scar formation over time after full-thickness incision injury in the rat. Wound Repair Regen. 2005 May-Jun; 13(3):309-17. PMID: 15953051.
        View in: PubMed
      34. Rodgers K, Roda N, Felix JE, Espinoza T, Maldonado S, diZerega G. Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice. Exp Dermatol. 2003 Dec; 12(6):784-90. PMID: 14714558.
        View in: PubMed
      35. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers K. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol. 2004 Jan; 53(1):15-24. PMID: 14569417.
        View in: PubMed
      36. Rodgers K, Verco SJ, diZerega GS. Effects of intraperitoneal 4% icodextrin solution on the healing of bowel anastomoses and laparotomy incisions in rabbits. Colorectal Dis. 2003 Jul; 5(4):324-30. PMID: 12814410.
        View in: PubMed
      37. Rodgers K, Robertson JT, Espinoza T, Oppelt W, Cortese S, diZerega GS, Berg RA. Reduction of epidural fibrosis in lumbar surgery with Oxiplex adhesion barriers of carboxymethylcellulose and polyethylene oxide. Spine J. 2003 Jul-Aug; 3(4):277-83; discussion 284. PMID: 14589186.
        View in: PubMed
      38. Rodgers K, Espinoza T, Felix J, Roda N, Maldonado S, diZerega G. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003 Mar; 111(3):1195-206. PMID: 12621191.
        View in: PubMed
      39. Conroy SE, Baines L, Rodgers K, Deviren F, Verco SJ. Prevention of chemotherapy-induced intraperitoneal adhesion formation in rats by icodextrin at a range of concentrations. Gynecol Oncol. 2003 Mar; 88(3):304-8. PMID: 12648579.
        View in: PubMed
      40. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol. 2003 Feb; 51(2):97-106. PMID: 12647010.
        View in: PubMed
      41. Rodgers K, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol. 2002 May; 49(5):403-11. PMID: 11976835.
        View in: PubMed
      42. Tan A, Rodgers K, Murrihy J, O'Mathuna C, Glennon JD. Rapid fabrication of microfluidic devices in poly(dimethylsiloxane) by photocopying. Lab Chip. 2001 Sep; 1(1):7-9. PMID: 15100882.
        View in: PubMed
      43. Rodgers K, Xiong S, Felix J, Roda N, Espinoza T, Maldonado S, Dizerega G. Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen. 2001 May-Jun; 9(3):238-47. PMID: 11472620.
        View in: PubMed
      44. Verco SJ, Peers EM, Brown CB, Rodgers K, Roda N, diZerega G. Development of a novel glucose polymer solution (icodextrin) for adhesion prevention: pre-clinical studies. Hum Reprod. 2000 Aug; 15(8):1764-72. PMID: 10920100.
        View in: PubMed
      45. Rodgers K, Xiong S, Espinoza T, Roda N, Maldonado S, diZerega GS. Angiotensin II increases host resistance to peritonitis. Clin Diagn Lab Immunol. 2000 Jul; 7(4):635-40. PMID: 10882664.
        View in: PubMed
      46. Rodgers K, Schwartz HE, Roda N, Thornton M, Kobak W, diZerega GS. Effect of oxiplex* films (PEO/CMC) on adhesion formation and reformation in rabbit models and on peritoneal infection in a rat model. Fertil Steril. 2000 Apr; 73(4):831-8. PMID: 10731549.
        View in: PubMed
      47. Jaibaji M, Brody GS, Rodgers K, Espinoza T, Roda N, Maldonado S, Pines E, diZerega G. A new model for experimental tendon adhesions in the chicken. Ann Plast Surg. 2000 Feb; 44(2):205-10. PMID: 10696049.
        View in: PubMed
      48. Rodgers K, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000; 18(4):287-94. PMID: 10924095.
        View in: PubMed
      49. Okuyama N, Wang CY, Rose EA, Rodgers K, Pines E, diZerega GS, Oz MC. Reduction of retrosternal and pericardial adhesions with rapidly resorbable polymer films. Ann Thorac Surg. 1999 Sep; 68(3):913-8. PMID: 10509983.
        View in: PubMed
      50. Okuyama N, Roda N, Sherman R, Guerrero A, Dougherty W, Nguyen T, diZerega G, Rodgers K. Angiotensin II improves random-flap viability in a rat model. Ann Plast Surg. 1999 Mar; 42(3):313-9. PMID: 10096624.
        View in: PubMed
      51. Rodgers K, Girgis W, Campeau J, diZerega GS. Reduction of adhesion formation by intraperitoneal administration of Arg-Gly-Asp-containing peptides. Fertil Steril. 1998 Dec; 70(6):1131-8. PMID: 9848306.
        View in: PubMed
      52. Rodgers K, Girgis W, St Amand K, Campeau JD, diZerega GS. Reduction of adhesion formation by intraperitoneal administration of various anti-inflammatory agents. J Invest Surg. 1998 Sep-Oct; 11(5):327-39. PMID: 9827650.
        View in: PubMed
      53. Rodgers K, Girgis W, St Amand K, Campeau J, diZerega GS. Reduction of adhesion formation in rabbits by intraperitoneal administration of lazaroid formulations. Hum Reprod. 1998 Sep; 13(9):2443-51. PMID: 9806265.
        View in: PubMed
      54. Okuyama N, Rodgers K, Wang CY, Girgis W, Oz M, St Amand K, Pines E, DeCherney AH, Rose EA, Cohn D, diZerega GS. Prevention of retrosternal adhesion formation in a rabbit model using bioresorbable films of polyethylene glycol and polylactic acid. J Surg Res. 1998 Aug; 78(2):118-22. PMID: 9733628.
        View in: PubMed
      55. Rodgers K, Cohn D, Hotovely A, Pines E, Diamond MP, diZerega G. Evaluation of polyethylene glycol/polylactic acid films in the prevention of adhesions in the rabbit adhesion formation and reformation sidewall models. Fertil Steril. 1998 Mar; 69(3):403-8. PMID: 9531866.
        View in: PubMed
      56. Rodgers K, Johns DB, Girgis W, diZerega GS. Prevention of adhesion formation with intraperitoneal administration of tolmetin and hyaluronic acid. J Invest Surg. 1997 Nov-Dec; 10(6):367-73. PMID: 9654393.
        View in: PubMed
      57. Rodgers K, Xiong S. Effect of administration of malathion for 90 days on macrophage function and mast cell degranulation. Toxicol Lett. 1997 Sep 19; 93(1):73-82. PMID: 9381485.
        View in: PubMed
      58. Rodgers K, DeCherney AH, St Amand KM, Dougherty WR, Felix JC, Girgis WW, diZerega GS. Histologic alterations in dermal repair after thermal injury effects of topical angiotensin II. J Burn Care Rehabil. 1997 Sep-Oct; 18(5):381-8. PMID: 9313116.
        View in: PubMed
      59. Rodgers K. Effects of oral administration of malathion on the course of disease in MRL-lpr mice. J Autoimmun. 1997 Aug; 10(4):367-73. PMID: 9237800.
        View in: PubMed
      60. Rodgers K, Xiong S. Effect of acute administration of malathion by oral and dermal routes on serum histamine levels. Int J Immunopharmacol. 1997 Aug; 19(8):437-41. PMID: 9568549.
        View in: PubMed
      61. Johns DB, Rodgers K, Donahue WD, Kiorpes TC, diZerega GS. Reduction of adhesion formation by postoperative administration of ionically cross-linked hyaluronic acid. Fertil Steril. 1997 Jul; 68(1):37-42. PMID: 9207581.
        View in: PubMed
      62. DeCherney AH, Dougherty WR, Felix JC, Rodgers K, Girgis W, Abiko M, diZerega GS. Expression of cyclin protein after thermal skin injury in a guinea pig model. J Burn Care Rehabil. 1997 Jul-Aug; 18(4):292-8. PMID: 9261693.
        View in: PubMed
      63. Xiong S, Rodgers K. Effects of malathion metabolites on degranulation of and mediator release by human and rat basophilic cells. J Toxicol Environ Health. 1997 Jun 6; 51(2):159-75. PMID: 9176556.
        View in: PubMed
      64. Rodgers K, Xiong S. Effect of administration of malathion for 14 days on macrophage function and mast cell degranulation. Fundam Appl Toxicol. 1997 May; 37(1):95-9. PMID: 9193927.
        View in: PubMed
      65. Rodgers K, Abiko M, Girgis W, St Amand K, Campeau J, diZerega G. Acceleration of dermal tissue repair by angiotensin II. Wound Repair Regen. 1997 Apr-Jun; 5(2):175-83. PMID: 16984428.
        View in: PubMed
      66. Rodgers K, Xiong S. Contributions of inflammatory mast cell mediators to alterations in macrophage function after malathion administration. Int J Immunopharmacol. 1997 Mar; 19(3):149-56. PMID: 9306154.
        View in: PubMed
      67. Rodgers K, Johns DB, Girgis W, Campeau J, diZerega GS. Reduction of adhesion formation with hyaluronic acid after peritoneal surgery in rabbits. Fertil Steril. 1997 Mar; 67(3):553-8. PMID: 9091346.
        View in: PubMed
      68. Rodgers K, Klykken P, Jacobs J, Frondoza C, Tomazic V, Zelikoff J. Immunotoxicity of medical devices. Symposium overview. Fundam Appl Toxicol. 1997 Mar; 36(1):1-14. PMID: 9073462.
        View in: PubMed
      69. Rodgers K, Girgis W, Campeau JD, diZerega GS. Reduction of adhesion formation by intraperitoneal administration of anti-inflammatory peptide 2. J Invest Surg. 1997 Jan-Apr; 10(1-2):31-6. PMID: 9100172.
        View in: PubMed
      70. Abiko M, Rodgers K, Campeau JD, Nakamura RM, Dizerega GS. Alterations of angiotensin II Receptor levels in sutured wounds in rat skin. J Invest Surg. 1996 Nov-Dec; 9(6):447-53. PMID: 8981218.
        View in: PubMed
      71. Rodgers K, Girgis W, Campeau JD, diZerega GS. Reduction of adhesion formation by intraperitoneal administration of a recombinant Hirudin analog. J Invest Surg. 1996 Sep-Oct; 9(5):385-91. PMID: 8951662.
        View in: PubMed
      72. Rodgers K, Xiong S. Contribution of mast cell mediators to alterations in macrophage function after malathion administration. Fundam Appl Toxicol. 1996 Sep; 33(1):100-8. PMID: 8812242.
        View in: PubMed
      73. Abiko M, Rodgers K, Campeau JD, Nakamura RM, Dizerega GS. Alterations of angiotensin II receptor levels in full-thickness excisional wounds in rat skin. Wound Repair Regen. 1996 Jul-Sep; 4(3):363-7. PMID: 17177733.
        View in: PubMed
      74. Rodgers K, St Amand K, Xiong S. Effects of malathion on humoral immunity and macrophage function in mast cell-deficient mice. Fundam Appl Toxicol. 1996 Jun; 31(2):252-8. PMID: 8789791.
        View in: PubMed
      75. LeGrand EK, Rodgers K, Girgis W, Campeau JD, Dizerega GS. Comparative efficacy of nonsteroidal anti-inflammatory drugs and anti-thromboxane agents in a rabbit adhesion-prevention model. J Invest Surg. 1995 May-Jun; 8(3):187-94. PMID: 7547726.
        View in: PubMed
      76. Sikorski EE, Kipen HM, Selner JC, Miller CM, Rodgers K. The question of multiple chemical sensitivity. Fundam Appl Toxicol. 1995 Jan; 24(1):22-8. PMID: 7713339.
        View in: PubMed
      77. Wiseman DM, Huang WJ, Johns DB, Rodgers K, Dizerega GS. Time-dependent effect of tolmetin sodium in a rabbit uterine adhesion model. J Invest Surg. 1994 Nov-Dec; 7(6):527-32. PMID: 7893639.
        View in: PubMed
      78. Rodgers K, Ellefson DD, Girgis W, diZerega GS. Modulation of postsurgical cell infiltration and fibrinolytic activity by tolmetin in two species. J Surg Res. 1994 Apr; 56(4):314-25. PMID: 8152224.
        View in: PubMed
      79. LeGrand EK, Rodgers K, Girgis W, Struck K, Campeau JD, diZerega GS, Kiorpes TC. Efficacy of tolmetin sodium for adhesion prevention in rabbit and rat models. J Surg Res. 1994 Jan; 56(1):67-71. PMID: 8277771.
        View in: PubMed
      80. Kuraoka S, Campeau JD, Rodgers K, Nakamura RM, diZerega GS. Modulation of cytotoxic activity of resident macrophages by postsurgical macrophages. J Surg Res. 1993 Oct; 55(4):397-403. PMID: 8412126.
        View in: PubMed
      81. Abe H, Campeau JD, Rodgers K, Ellefson DD, Girgis W, diZerega GS. Peritoneal lavage fluid protease levels after in vivo administration of tolmetin in hyaluronic acid. J Surg Res. 1993 Oct; 55(4):451-6. PMID: 8412132.
        View in: PubMed
      82. Rodgers K, diZerega GS. Function of peritoneal exudate cells after abdominal surgery. J Invest Surg. 1993 Jan-Feb; 6(1):9-23. PMID: 8452827.
        View in: PubMed
      83. Rodgers K, diZerega GS. Modulation of peritoneal re-epithelialization by postsurgical macrophages. J Surg Res. 1992 Nov; 53(5):542-8. PMID: 1434606.
        View in: PubMed
      84. Rodgers K, Abe H, Campeau JD, Ellefson DD, Girgis W, diZerega GS. In vivo administration of tolmetin in hyaluronic acid modulates protease levels in postsurgical macrophage-conditioned media. J Invest Surg. 1992 Oct-Dec; 5(4):285-96. PMID: 1472482.
        View in: PubMed
      85. Rodgers K, Ellefson D, Girgis W, diZerega GS. Protease and protease inhibitor secretion by postsurgical macrophages following in vitro exposure to tolmetin. Agents Actions. 1992 Jul; 36(3-4):248-57. PMID: 1326879.
        View in: PubMed
      86. Albertson BD, Rodgers K, Tomai TP, Nolan-Watson K, Zinaman MJ, DiZerega GS. Enhanced follicle regulatory protein levels accompany reinitiation of ovulatory function after parturition. Am J Obstet Gynecol. 1992 Jul; 167(1):158-62. PMID: 1442919.
        View in: PubMed
      87. Rodgers K, Girgis W, diZerega GS. Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antineoplastic agents. Cancer Chemother Pharmacol. 1992; 29(3):248-51. PMID: 1370766.
        View in: PubMed
      88. Rodgers K, Ellefson D. Mechanism of the modulation of murine peritoneal cell function and mast cell degranulation by low doses of malathion. Agents Actions. 1992 Jan; 35(1-2):57-63. PMID: 1387283.
        View in: PubMed
      89. Kuraoka S, Campeau JD, Rodgers K, Nakamura RM, diZerega GS. Effects of interleukin-1 (IL-1) on postsurgical macrophage secretion of protease and protease inhibitor activities. J Surg Res. 1992 Jan; 52(1):71-8. PMID: 1312652.
        View in: PubMed
      90. Abe H, Rodgers K, Ellefson D, diZerega GS. Kinetics of interleukin-1 and tumor necrosis factor secretion by rabbit macrophages recovered from the peritoneal cavity after surgery. J Invest Surg. 1991; 4(2):141-51. PMID: 2069924.
        View in: PubMed
      91. Abe H, Rodgers K, Campeau JD, Girgis W, Ellefson D, DiZerega GS. The effect of intraperitoneal administration of sodium tolmetin-hyaluronic acid on the postsurgical cell infiltration in vivo. J Surg Res. 1990 Oct; 49(4):322-7. PMID: 2214740.
        View in: PubMed
      92. Rodgers K, Girgis W, diZerega GS, Bracken K, Richer L. Inhibition of postsurgical adhesions by liposomes containing nonsteroidal antiinflammatory drugs. Int J Fertil. 1990 Sep-Oct; 35(5):315-20. PMID: 1980669.
        View in: PubMed
      93. Fukasawa M, Campeau JD, Yanagihara DL, Rodgers K, diZerega GS. Regulation of proliferation of peritoneal tissue repair cells by peritoneal macrophages. J Surg Res. 1990 Jul; 49(1):81-7. PMID: 2359298.
        View in: PubMed
      94. Rodgers K, Marks JF, Ellefson DD, Yanagihara DL, Tonetta SA, Vasilev SA, Morrow CP, Montz FJ, diZerega GS. Follicle regulatory protein: a novel marker for granulosa cell cancer patients. Gynecol Oncol. 1990 Jun; 37(3):381-7. PMID: 1693585.
        View in: PubMed
      95. Rodgers K, Ellefson DD. Modulation of macrophage protease activity by acute administration of O,O,S trimethyl phosphorothioate. Agents Actions. 1990 Mar; 29(3-4):277-85. PMID: 2160188.
        View in: PubMed
      96. Rodgers K, Ellefson DD. Modulation of respiratory burst activity and mitogenic response of human peripheral blood mononuclear cells and murine splenocytes and peritoneal cells by malathion. Fundam Appl Toxicol. 1990 Feb; 14(2):309-17. PMID: 2318355.
        View in: PubMed
      97. Abe H, Rodgers K, Campeau JD, Girgis W, Dizerega GS. Temporal response of leukocyte accumulation in the thoracic cavity after two types of surgical injury. J Invest Surg. 1990; 3(1):51-63. PMID: 2282349.
        View in: PubMed
      98. Rodgers K. Nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of postsurgical adhesion. Prog Clin Biol Res. 1990; 358:119-29. PMID: 2217487.
        View in: PubMed
      99. Rodgers K, Girgis W, diZerega GS, Johns DB. Intraperitoneal tolmetin prevents postsurgical adhesion formation in rabbits. Int J Fertil. 1990 Jan-Feb; 35(1):40-5. PMID: 1968443.
        View in: PubMed
      100. Abe H, Rodgers K, Ellefson D, DiZerega GS. Kinetics of interleukin-1 secretion by murine macrophages recovered from the peritoneal cavity after surgery. J Surg Res. 1989 Aug; 47(2):178-82. PMID: 2787874.
        View in: PubMed
      101. Fukasawa M, Yanagihara DL, Rodgers K, DiZerega GS. The mitogenic activity of peritoneal tissue repair cells: control by growth factors. J Surg Res. 1989 Jul; 47(1):45-51. PMID: 2739400.
        View in: PubMed
      102. Rodgers K, Haviland DL, Ware CF. Protection from O,O,S-trimethyl phosphorothioate-induced immune suppression. Immunopharmacology. 1989 May-Jun; 17(3):131-40. PMID: 2767956.
        View in: PubMed
      103. Fukasawa M, Campeau JD, Girgis W, Bryant SM, Rodgers K, DiZerega GS. Production of protease inhibitors by postsurgical macrophages. J Surg Res. 1989 Mar; 46(3):256-61. PMID: 2493532.
        View in: PubMed
      104. Rodgers K, Stern ML, Ware CF. Effects of subacute administration of O,S,S-trimethyl phosphorodithioate on cellular and humoral immune response systems. Toxicology. 1989 Feb; 54(2):183-95. PMID: 2784238.
        View in: PubMed
      105. Fukasawa M, Campeau JD, Yanagihara DL, Rodgers K, Dizerega GS. Mitogenic and protein synthetic activity of tissue repair cells: control by the postsurgical macrophage. J Invest Surg. 1989; 2(2):169-80. PMID: 2487245.
        View in: PubMed
      106. Rodgers K, Montz FJ, Scott L, Condon S, Fujimori K, diZerega GS. Inhibition of ovarian cancer cell proliferation in vivo and incorporation of 3H-thymidine in vitro after follicle regulatory protein administration. Obstet Gynecol. 1989 Jan; 73(1):66-74. PMID: 2909044.
        View in: PubMed
      107. Rodgers K, Leung N, Ware CF. Effects of acute administration of O,S,S-trimethyl phosphorodithioate on the generation of cellular and humoral immune responses following in vitro stimulation. Toxicology. 1988 Oct; 51(2-3):241-53. PMID: 3051516.
        View in: PubMed
      108. Rodgers K, Ellefson DD. Effects of acute administration of O,O,S-trimethyl phosphorothioate on the respiratory burst and phagocytic activity of splenic and peritoneal leukocytes. Agents Actions. 1988 Jun; 24(1-2):152-60. PMID: 2841830.
        View in: PubMed
      109. Katt E, Fujimori K, Yanagihara D, Campeau J, Numazaki M, Holst P, Tonetta S, Rodgers K, Westhof G, Mishell D. Determination of follicle regulatory protein levels in urine during the normal menstrual cycle using an enzyme-linked immunosorbant assay. J Clin Endocrinol Metab. 1988 Jun; 66(6):1213-9. PMID: 3372684.
        View in: PubMed
      110. Fujimori K, Rodgers K, Nakamura RM, Katt E, Yanagihara DL, diZerega GS. Localization of follicle regulatory protein in the porcine ovary. J Histochem Cytochem. 1988 Jun; 36(6):589-95. PMID: 3367045.
        View in: PubMed
      111. Rodgers K, Grayson MH, Ware CF. Inhibition of cytotoxic T lymphocyte and natural killer cell-mediated lysis by O,S,S,-trimethyl phosphorodithioate is at an early postrecognition step. J Immunol. 1988 Jan 15; 140(2):564-70. PMID: 3257244.
        View in: PubMed
      112. Rodgers K, Tonetta SA, diZerega GS. Development of an enzyme-linked immunoassay for follicle regulatory protein. Prog Clin Biol Res. 1988; 285:221-36. PMID: 3231646.
        View in: PubMed
      113. Rodgers K, Ellefson D, Girgis W, Scott L, diZerega GS. Effects of tolmetin sodium dihydrate on normal and postsurgical peritoneal cell function. Int J Immunopharmacol. 1988; 10(2):111-9. PMID: 2836323.
        View in: PubMed
      114. Bryant SM, Fukasawa M, Orita H, Rodgers K, diZerega GS. Mediation of post-surgical wound healing by macrophages. Prog Clin Biol Res. 1988; 266:273-90. PMID: 3380849.
        View in: PubMed
      115. Lew MW, Katt EL, Rodgers K, diZerega GS. Alteration of follicle regulatory protein levels in human reproductive disorders: anovulation. Obstet Gynecol. 1987 Aug; 70(2):157-62. PMID: 3601276.
        View in: PubMed
      116. Rodgers K, Imamura T, Devens BH. Investigations into the mechanism of immunosuppression caused by acute treatment with O,O,S-trimethyl phosphorothioate: generation of suppressive macrophages from treated animals. Toxicol Appl Pharmacol. 1987 Apr; 88(2):270-81. PMID: 3494328.
        View in: PubMed
      117. Rodgers K, Leung N, Ware CF, Imamura T. Effects of O,S,S-trimethyl phosphorodithioate on immune function. Toxicology. 1987 Feb; 43(2):201-16. PMID: 3492784.
        View in: PubMed
      118. Rodgers K, Imamura T, Devens BH. Organophosphorus pesticide immunotoxicity: effects of O,O,S-trimethyl phosphorothioate on cellular and humoral immune response systems. Immunopharmacology. 1986 Dec; 12(3):193-202. PMID: 3493228.
        View in: PubMed
      119. Koizumi A, Hasegawa L, Rodgers K, Ellefson D, Walford RL, Imamura T. Influence of H-2 haplotypes on poly IC induction of xanthine oxidase and poly IC induced decreases in P-450 mediated enzyme activities. Biochem Biophys Res Commun. 1986 Jul 16; 138(1):246-53. PMID: 3755596.
        View in: PubMed
      120. Rodgers K, Imamura T, Devens BH. Investigations into the mechanism of immunosuppression caused by acute treatment with O,O,S-trimethyl phosphorothioate. II. Effect on the ability of murine macrophages to present antigen. Immunopharmacology. 1985 Dec; 10(3):181-9. PMID: 3833856.
        View in: PubMed
      121. Rodgers K, Imamura T, Devens BH. Investigations into the mechanism of immunosuppression caused by acute treatment with O,O,S-trimethyl phosphorothioate. I. Characterization of the immune cell population affected. Immunopharmacology. 1985 Dec; 10(3):171-80. PMID: 2939039.
        View in: PubMed
      122. Rodgers K, Imamura T, Devens BH. Effects of subchronic treatment with O,O,S-trimethyl phosphorothioate on cellular and humoral immune response systems. Toxicol Appl Pharmacol. 1985 Nov; 81(2):310-8. PMID: 3877352.
        View in: PubMed